US EditionBellvitge Leads the First Clinical Trial Evaluating the Antifibrotic Benefit in Patients with Post-Covid Fibrosis
Summary by Salud a Diario
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
The study concludes that although there are no significant differences in the number of patients who improved lung damage caused by severe covid-19-induced acute respiratory distress syndrome, the degree of improvement was higher in the group who received pyrfenidone added to the low doses of oral corticosteroids they already received. This is the first randomized clinical trial that evaluates the efficacy and safety of pyrfenidone, an antifibro…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
